Bajaj Healthcare Limited reported a net profit of ₹13.7 crore for the quarter ended June 30, 2026, an increase of 15.8% compared to the same period last year, driven by robust domestic API sales and expanding margins. During its first-ever earnings call on July 21, 2026, management provided forward-looking guidance, projecting revenue growth of 10% to 15% for FY27, supported by stable API prices and volume-led expansion in the domestic segment.

The company’s revenue from operations grew 11.3% year-on-year to ₹165.63 crore, while EBITDA margins expanded to 17.8% from 17.0% in Q1FY26. Managing Director Anil Jain highlighted that domestic API sales rose 27.1% year-on-year to ₹92.26 crore, offsetting a decline in export sales due to geopolitical disruptions in West Asia. The improved financial performance was further bolstered by a sequential revenue growth of 8.2% from ₹153.06 crore in the preceding quarter.

Financial Performance

Profit after tax (PAT) margin improved to 8.3% from 8.0% in the prior year. Gross profit increased 16.2% to ₹80.4 crore, with gross margins expanding to 48.3% from 46.2% in Q1FY26. Chief Financial Officer Rohan Parekh noted that net worth stood at ₹533 crore as of March 31, 2026, up from ₹466 crore last year, with the debt-to-equity ratio improving to 0.45 from 0.48 in FY25.

Strategic Initiatives and Pipeline

Bajaj Healthcare secured a recommendation from the US Securities and Exchange Commission (SEC) for Cenobamate Tablets, a milestone for commercializing this anti-seizure medication. The company expects to generate ₹10–12 crore in revenue from this product in FY27. Additionally, Bajaj Oncocare, launched in 2024, now operates across 23 states with over 15 brands. The company is also advancing its peptide manufacturing facility, targeting commissioning by Q4 2027, with initial production focused on Semaglutide for the Indian market.

What the Numbers Show

The divergence between domestic API growth (27.1%) and export declines highlights a strategic shift towards high-margin domestic markets and specialty formulations. With receivable days improving from 145 to 131 days, management anticipates further working capital optimization. The planned capex of ₹40–50 crore annually will fund backward integration in Vitamin C and other key molecules, aiming to reduce dependency on Chinese raw materials and enhance long-term margins.

Regulatory Disclosure

In an intimation under Regulation 30 of SEBI (LODR) Regulations, 2015, the company confirmed that the transcript of the earnings call held on July 21, 2026, has been uploaded to its website. The company filed two CEP applications during the quarter, bringing cumulative filings to twelve, with eight approved and four under review.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE411U01027/9aebc345-6dab-4c87-a71c-8b7e6878bd38.pdf

Bajaj Healthcare Limited granted 275 stock options to an eligible employee under its Bajaj Healthcare Limited Employee Stock Option Plan 2024. The Nomination & Remuneration Committee approved the grant at an exercise price of ₹5 per option on July 20, 2026. Each option is convertible into one fully paid-up equity share with a face value of ₹5, covering a total of 275 equity shares.

The scheme is in terms of the SEBI (SBEB) Regulations, 2021. Options vest over a maximum period of four years from the date of grant, with a minimum period of one year between the grant and vesting. Vested options may be exercised by the grantee within five years from the date of vesting.

Grant Details

Eligibility for participation includes employees working in India or abroad, and directors who are not promoters or independent directors. The scheme excludes employees who are promoters or belong to the promoter group, as well as independent directors. Shares arising from the exercise of options are not subject to a lock-in period, though trading restrictions under the company's insider trading code apply.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.